Abstract: A vinylpyridine resin for a catalyst support; a method for producing thereof; and a catalyst for carbonylation of methanol are disclosed. The vinylpyridine resin has: content of nitrogen derived from a pyridine group of 3.00% by mass or more and 8.00% by mass or less; degree of crosslinking of 35% by mole or more and 70% by mole or less; molar ratio C/N of carbon atoms to nitrogen atoms of 12.00 or more and 36.00 or less; total pore volume of 0.20 cc/g or more and 0.45 cc/g or less; specific surface area of 70.0 m2/g or more and 280 m2/g or less; average pore diameter of 5.0 nm or more and 25.0 nm or less; and proportion of a volume of pores having a pore diameter of 10 nm or more to a volume of the whole pores of 4.0% or more and 90.0% or less.

Abstract: A vinylpyridine resin for a catalyst support; a method for producing thereof; and a catalyst for carbonylation of methanol are disclosed. The vinylpyridine resin has: content of nitrogen derived from a pyridine group of 3.00% by mass or more and 8.00% by mass or less; degree of crosslinking of 35% by mole or more and 70% by mole or less; molar ratio C/N of carbon atoms to nitrogen atoms of 12.00 or more and 36.00 or less; total pore volume of 0.20 cc/g or more and 0.45 cc/g or less; specific surface area of 70.0 m2/g or more and 280 m2/g or less; average pore diameter of 5.0 nm or more and 25.0 nm or less; and proportion of a volume of pores having a pore diameter of 10 nm or more to a volume of the whole pores of 4.0% or more and 90.0% or less.

Abstract: This invention provides a carrier for a synthesis gas production catalyst that can suppress carbon depositions and allows to efficiently produce synthesis gas on a stable basis for a long duration of time when producing synthesis gas by carbon dioxide reforming. It is a carrier to be used for producing synthesis gas containing carbon monoxide and hydrogen from source gas containing methane-containing light hydrocarbons and carbon dioxide. The carrier contains magnesium oxide grains and calcium oxide existing on the surfaces of magnesium oxide grains. The calcium oxide content thereof is between 0.005 mass % and 1.5 mass % in terms of Ca.

Abstract: This invention provides a carrier for a synthesis gas production catalyst that can suppress carbon depositions and allows to efficiently produce synthesis gas on a stable basis for a long duration of time when producing synthesis gas by carbon dioxide reforming. It is a carrier to be used for producing synthesis gas containing carbon monoxide and hydrogen from source gas containing methane-containing light hydrocarbons and carbon dioxide. The carrier contains magnesium oxide grains and calcium oxide existing on the surfaces of magnesium oxide grains. The calcium oxide content thereof is between 0.005 mass % and 1.5 mass % in terms of Ca.

Abstract: Provided is a method of evaluating a resin capable of quantitatively evaluating a deterioration degree of the resin with high accuracy and ease. The method includes evaluating the resin based on a shift of a characteristic peak representing a deterioration degree of the resin, the peak being observed in thermal analysis of the resin by a temperature increase, to lower temperatures.

Abstract: Provided is a method of evaluating a resin capable of quantitatively evaluating a deterioration degree of the resin with high accuracy and ease. The method includes evaluating the resin based on a shift of a characteristic peak representing a deterioration degree of the resin, the peak being observed in thermal analysis of the resin by a temperature increase, to lower temperatures.

Abstract: The invention, in some aspects, relates to the selective killing of cancer stem cells by oncolytic Herpes virus mediated oncolysis. In some aspects, the invention relates to methods for treating a subject having a cancer stem cell by administering to the subject an oncolytic Herpes virus. In other aspects, the invention provides methods for evaluating the efficacy of an oncolytic Herpes virus for killing cancer stem cells.

Abstract: The invention, in some aspects, relates to the selective killing of cancer stem cells by oncolytic Herpes virus mediated oncolysis. In some aspects, the invention relates to methods for treating a subject having a cancer stem cell by administering to the subject an oncolytic Herpes virus. In other aspects, the invention provides methods for evaluating the efficacy of an oncolytic Herpes virus for killing cancer stem cells.

Abstract: The present invention provides a recombinant HSV having the ability to specifically kill tumor cells such as human glioma cells in vivo, useful and safe for treating human glioma, etc. and that can easily put to clinical use. A new recombinant HSV, KeM345, is constructed by inserting a ?34.5 gene transcription unit, which is expressed by Musashi1 promoter, into a ribonucleotide reductase gene site of the genome of a herpes simplex virus (HSV) previously attenuated, by means of homologous recombination and obtained as a purified strain. Since KeM345 is a recombinant virus itself, it can not only induce viral proliferation by being transmitted to culture cells but can also induce viral replication equivalent to that of wild-type HSV, showing an excellent cytotoxic effect (cytolytic ability) selectively upon a malignant glioma.

Abstract: The present invention provides a recombinant HSV having the ability to specifically kill tumor cells such as human glioma cells in vivo, useful and safe for treating human glioma, etc. and that can easily put to clinical use. A new recombinant HSV, KeM345, is constructed by inserting a ?34.5 gene transcription unit, which is expressed by Musashil promoter, into a ribonucleotide reductase gene site of the genome of a herpes simplex virus (HSV) previously attenuated, by means of homologous recombination and obtained as a purified strain. Since KeM345 is a recombinant virus itself, it can not only induce viral proliferation by being transmitted to culture cells but can also induce viral replication equivalent to that of wild-type HSV, showing an excellent cytotoxic effect (cytolytic ability) selectively upon a malignant glioma.

Abstract: A process for the wet processing of a dioxin-containing material, wherein the material is contacted with an aqueous solution, acidified with hydrochloric acid and containing a catalyst dissolved therein, at a temperature lower than 100° C. to decompose the dioxins into harmless substances with a decomposition rate of at least 60%.